Improved Selectivity against Acute Myeloid Leukemia (AML) Blasts Over Normal Hematopoietic Progenitors for Cytarabine: Daunorubicin Delivered as CPX-351 Liposome Injection.
Notice bibliographique
Résumé
Abstract Abstract 2071 Poster Board II-48 Background: Combinations of cytarabine (Ara-C) and daunorubicin (DNR) have been the mainstay of induction chemotherapy for AML for three decades. Although many patients achieve a complete remission (CR), at least 20% have leukemia that is refractory (NR) to this treatment and the majority of the remainder eventually relapse with chemotherapy resistant disease. One of the main mechanisms of multidrug resistance in AML is over-expression of ATP-binding cassette (ABC) transporters such as MDR-1 and BCRP-1. CPX-351 is a liposomal formulation of Ara-C and DNR in which the ratio of the two drugs encapsulated (5:1, mol:mol) has been designed to maximize synergistic interactions. In addition, preclinical studies demonstrated a prolonged half-life of 24 to 36h and markedly improved in vivo efficacy against animal leukemia models for CPX-351. More recently, encouraging Phase 1 trial results in patients with advanced acute leukemia have resulted in continued clinical development of this drug in a Phase 2 setting. The purpose of this study was to compare the relative sensitivity of colony forming cells (CFC) from AML patient blast samples and normal blood (PB) and marrow (BM) to CPX-351 and the same concentrations of free Ara-C and DNR (FD). Investigations of the relative sensitivity of AML blasts from CR and NR patients to CPX-351 as well as the intracellular accumulation and sub-cellular localization of the liposomal drugs were undertaken in an attempt to elucidate the basis for the putative improved efficacy observed with CPX-351. Methods: A panel of AML patient blast samples (including CR and NR to induction chemotherapy) as well as normal PB and BM samples were assessed for drug sensitivity by incubating cells for 24h in various concentrations of CPX-351 or the same concentrations of FD prior to plating in CFC assays with or without ABC transporter inhibition by cyclosporine A (CA). Quantitative RT-PCR was used to measure expression of the ABC transporter proteins MDR-1 and BCRP-1. HPLC and confocal microscopy were used to study the cellular drug uptake and subcellular distribution of CPX-351, respectively. Results: Comparison of the IC50 values obtained against AML-CFC for CPX-351 and FD demonstrated no significant difference in progenitor kill despite the fact that drug release from CPX-351 liposomes in media was negligible under exposure conditions, suggesting direct uptake of CPX-351 liposomes by the leukemia cells. However, CPX-351 was approximately 3-fold less cytotoxic against normal PB and BM CFC than FD. CPX-351 was also 3-9-fold more potent against AML-CFC than against normal CFC while the same comparison for FD showed less than a 3-fold difference. HPLC demonstrated accumulation of CPX-351 in AML blasts and confocal microscopy showed the presence of liposomes in the cytoplasm and daunorubicin within the cytoplasm and nucleus of these cells. AML blasts from NR patients showed expression of MDR-1 and/or BCRP-1 which was 3.5 to >200-fold higher than that shown in blasts from CR patients. There was no consistent difference in qualitative induction of AML blast cell apoptosis between CPX-351 and FD with either the CR or the NR samples. However, the addition of CA, which had no effect on the CR sample treated with either CPX-351 or FD, rendered the NR samples more susceptible to both CPX-351 and FD. Interestingly, the CA-induced increase in cell kill was greater with CPX-351 than with FD. Conclusions: CPX-351 exhibits less toxicity against normal PB and BM progenitors than against AML blast CFC and this difference is greater than that seen with conventional cytarabine and daunorubicin. The CPX-351 liposomes appear to enter blast cells and subsequently release their contents where they can be detected in both the cytoplasm and the nucleus. These data suggest an enhanced specificity for the CPX-351 liposomal formulation of cytarabine and daunorubicin against AML over normal hematopoietic progenitors as well as potential differences in cellular uptake and metabolism as compared to the free chemotherapy drugs that may provide a therapeutic advantage. Disclosures: No relevant conflicts of interest to declare.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».